Advocates, Physicians and Entertainers to Gather for Low Dose Naltrexone Conference

Advocates, Physicians and Entertainers to Gather for Low Dose Naltrexone Conference

BETHESDA, Md., March 13 /PRNewswire/ -- On April 7, 2006, physicians, patient advocates and entertainers will gather at the Second Annual Low Dose Naltrexone (LDN) Conference (http://www.lowdosenaltrexone.org/) to bring awareness to a promising treatment for HIV/AIDS, cancer, multiple sclerosis (MS), autism and a host of other life-altering autoimmune conditions.

Naltrexone was originally approved by the FDA in 1984 at the 50mg level for narcotics addiction. But around the world, physicians and researchers are discovering that at much lower doses -- most commonly in the 4.5mg range -- the compounded medication, taken nightly, stimulates the immune system and helps the body fight off devastating diseases. LDN has no known harmful side effects, and at an average price of under $50 per month's supply, the compound is extremely affordable.

Still, LDN remains largely unknown in the U.S. - and according to Susan Sedlock, coordinator of the Second Annual LDN Conference, big pharma remains uninterested in LDN, perhaps because of naltrexone's status as a generic drug and LDN's extremely low cost to the patient.

But if Sedlock and the speakers at the Second Annual LDN Conference have anything to say about it, many more patients will soon know about LDN.

The event's theme, "The Future Is Now," reflects the strides made in LDN research and clinical trials in the past year. On the schedule are: Dr. David Gluck, host of last year's conference, with a brief review of the year in LDN; keynote speaker Dr. Jill Smith, professor of gastroenterology at Pennsylvania State University, who will discuss her impressions of the first LDN clinical trial in the U.S., in which she studied the compound's effects on Crohn's disease; Dr. Jacqueline McCandless, who will present her achievements using LDN in treating childhood autism and report findings from parents whose children with bipolar disorder are responding to LDN; Dr. Phil Boyle, a family physician in Ireland, who will discuss some "stunning clinical results"; and Dr. Pat Crowley, also from Ireland, who will show his documentary on LDN treatment.

Singer/songwriter Paul Nicholas, who debuted his hit song "Please Remember Me," now the anthem in the fight against MS, on the Montel Williams Show in June, will perform at the Second Annual LDN Conference. Nicholas, who has MS, recently began taking LDN and has experienced dramatic improvements. As a result, Nicholas has waived his performance fee for the conference in an effort to promote recognition of LDN as a viable treatment for MS.

The Second Annual LDN Conference will be held on the campus of the National Institutes of Health in the Lister Hill Center Auditorium of the National Library of Medicine. For additional information, visit http://www.lowdosenaltrexone.org/.

Contact:

Susan Sedlock
Second Annual Low Dose Naltrexone Conference
703-998-0272
2002eldo@msn.comhttp://www.lowdosenaltrexone.org/

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

Source: Second Annual Low Dose Naltrexone Conference

CONTACT: Susan Sedlock for the Second Annual Low Dose Naltrexone
Conference, +1-703-998-0272, 2002eldo@msn.com

Web site: http://www.lowdosenaltrexone.org/

-------
Profile: intent